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Introduction
Clinical trials in multiple sclerosis (MS) have led 
to the introduction of 15 therapeutic agents in the 
span of just over two decades. Prior to the mod-
ern era of these MS therapies, initial treatments of 
the disease during the early 20th century were 
empirical or experience driven and studies on 
potential agents were scarce and unregulated. 
Investigators noted many difficulties in conduct-
ing clinical trials in MS. The incomplete under-
standing of the disease process hindered 
development of therapies, and the sporadic course 
of MS coupled with the lack of biomarkers cre-
ated difficulties in monitoring disease progres-
sion. In order to detect differences in treatments, 
large patient populations must be followed for 
long durations due to the slow evolution of clini-
cal changes. Trials are often seen as more efficient 
when the population is more homogeneous. 
Thus, the heterogeneity of the disease excluded 
many patients with MS from trials due to narrow 
inclusion criteria. Despite these challenges, the 
significant achievements in MS therapies today 
relied directly on clinical trials that proved their 
efficacy. This article reviews key events and devel-
opments that shaped the landscape of MS clinical 
trials.
Early studies
The first clinical trials in MS took place in the 
second half of the 20th century. Early trials were 
limited in their design due to lack of established 
criteria for diagnosing MS and objective measure-
ments of disease progression. In 1961, Miller and 
colleagues published the results of the first dou-
ble-blind clinical trial in MS studying the effects 
of adrenocorticotropic hormone (ACTH) on 
neurological recovery during acute MS exacerba-
tions.1 The study enrolled 40 “consecutive 
patients with unequivocal MS, who presented 
with an assessable new symptom or sign of less 
than 14 days’ duration and showing no spontane-
ous improvement”. Subjects were matched in 
sex, age, disease duration, and number of exacer-
bations, and randomized to receive either ACTH 
or saline injections for their MS attacks. The 
authors stated that “the groups were generally 
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comparable in sex-distribution, age, and duration 
of the disease, as well as in the proportions classi-
fied as showing initial episodes of multiple sclero-
sis, second or subsequent attacks during 
remission, or acute exacerbations of an existing 
disability of less than 10 years’ standing”. 
However, if one were to look critically, it is likely 
that the two groups were poorly matched, as it 
was difficult to do this sequentially with a small 
sample size. Results showed that ACTH improved 
symptoms during an exacerbation, but this was 
measured entirely through subjective reports 
from patients in a follow-up interview.
At the time, the absence of established and objec-
tive outcome measurements along with the uncer-
tainty of characterizing relapses hindered studies 
from producing reliable data. The sporadic nature 
of the disease challenged investigators to not only 
find promising treatments but to devise ways to 
assess their efficacy. In 1969, Rose and colleagues 
conducted the first multicenter MS trial across 10 
academic institutions in the USA.2,3 This was 
another well-controlled, randomized double-
blind trial to study ACTH in the treatment of MS 
attacks. More importantly, the study aimed to 
determine whether a therapeutic agent can be 
reliably assessed. The investigators employed var-
ious quantitative methods to assess neurologic 
functions, among which was the disability status 
scale (DSS), that would be revised later to become 
the golden standard of outcome measures in MS 
trials.4 The study concluded that therapeutic 
agents can be objectively studied in patients with 
MS. Although results suggested only modest 
effects of ACTH in the setting of MS exacerba-
tion, ACTH was widely employed for the treat-
ment of MS for the next 15 years, eventually 
leading to high-dose intravenous methylpredniso-
lone as a treatment for MS exacerbations.
Advancement of imaging techniques
Another major evolution over time is the growth 
and importance of magnetic resonance imaging 
(MRI) in the diagnosis of MS and monitoring of 
disease activity. This technology now has wide-
spread use in clinical trials and has been central in 
proof-of-concept studies. Prior to the develop-
ment of MRI, computerized tomography (CT) 
scans were unable to identify most MS lesions, 
and many patients with MS had normal CT 
scans. When contrast CT scans were first intro-
duced to study MS lesions in 1976, enhancing 
lesions could be seen and became associated with 
so-called active disease.5 These lesions also 
appeared to clear with steroid use.6 When MRI 
was initially utilized in studies of MS in 1981, 
researchers immediately noticed striking differ-
ences between MRI and CT regarding the appear-
ance of lesions. In one of the early studies 
comparing the two imaging modalities among 10 
patients with definite and possible MS, CT cap-
tured 19 lesions whereas MRI captured 131 
lesions.7 MRI showed continuous activity of new 
lesions even in the absence of clinical symptoms, 
suggesting its usefulness in monitoring subclinical 
disease progression.8 In addition, imaging out-
comes are more sensitive to change than clinical 
measures, thus requiring smaller sample size and 
study duration to detect treatment differences. 
This is especially valuable for early proof-of-con-
cept trials but may be tied to the main focus of 
clinical interventions thus far in MS of reducing 
inflammation and the attendant consequences. 
The utility of other pathways of damage such as 
neuroprotection and/or neurorepair has yet to be 
shown.
In the 1990s MRI became a popular tool for pro-
viding secondary and even primary outcome 
measures in drug studies. In the 5-year, 1988–
1993, placebo-controlled trial of interferon-beta-
1b that showed a significant reduction in the 
frequency of MS attacks in the treatment group, 
MRI was used as an outcome measure and 
showed 80% fewer active scans and new lesion 
developments compared with placebo.9 The evi-
dence was perhaps even more compelling biologi-
cally than the clinical data in the US Food and 
Drug Administration’s (FDA) approval of the 
drug in 1993. As MRI became more widely used 
in clinical trials, researchers gained a better 
understanding of its utilities and limitations. 
Many MS trials have used MRI to measure dis-
ease burden and monitor disease activity.10 The 
use of gadolinium contrast showing enhancement 
of lesions indicating active blood-brain-barrier 
breakdown has been an important tool in con-
firming active MS lesions.11 In addition to meas-
uring lesions, MRI has also been used to assess 
unfractionated or fractionated atrophy, which 
corresponds to some clinical disease markers.12 
Despite these utilities, MRI lesions found on a 
single or annual basis have not consistently been 
shown to correlate with individual clinical out-
comes in trials.13 However, Sormani and col-
leagues have shown that at the group level such 
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correlations do exist.14 Despite the radiologic util-
ity of MRI, there is a need for improved MRI and 
clinical methods to characterize accurately dis-
ease states and quantify progression.
Evolution of diagnostic criteria for MS
The diagnosis of MS and classification of its dis-
ease course have important implications for clin-
ical trial design and outcomes. MS presents with 
varying clinical signs and symptoms and follows 
unpredictable disease courses, making it difficult 
for trials to acquire homogeneous populations to 
be able to determine differences in treatment 
effects. Finding these so-called homogeneous 
groups has been a challenge. Since the first for-
mal diagnostic criteria of MS in 1965 that intro-
duced the principles of dissemination in space 
(DIS) and time (DIT),15 progress in our under-
standing of the disease and tools to study its 
clinical course have led to more accurate and 
simplified criteria.
Early attempts to diagnose and categorize MS 
focused on identifying clinical patterns of symp-
toms as exemplified by Charcot’s triad of nys-
tagmus, intention tremor, and scanning 
speech.16 Other classifications sorted patients 
into categories corresponding to disease course 
as defined by progression and relapses.17,18 
There was a lack of unified guidelines, and diag-
noses relied heavily on the clinician’s intuition 
rather than objective guidelines. The first incor-
poration of the modern-day diagnostic require-
ment of DIS and DIT was presented in the 
Schumacher criteria in 1965 as a result of a 
committee headed by George Schumacher to 
develop criteria for classifying MS.15 DIS was 
defined as objective abnormalities in at least two 
central nervous system white matter locations, 
while DIT described their occurrence in two or 
more episodes lasting more than 24 hours and 
separated by at least 1 month or progressing 
over 6 months. The Schumacher criteria simpli-
fied MS trial design and allowed for objective 
diagnosis of clinically definite MS.15
With the development of laboratory and imaging 
studies to diagnose MS, Poser published criteria 
in 1983 that incorporated paraclinical studies 
such as imaging and cerebrospinal fluid (CSF) 
studies in the diagnosis of MS.19 The Poser crite-
ria elaborated on the clinical classifications of the 
Schumacher criteria and grouped patients into 
categories of definite and probable MS.20 This 
became widely accepted as the diagnosis of MS 
and altered the enrollment criteria of clinical trials 
to accept only clinically definite and probable 
cases of MS.
The widespread use of MRI in the evaluation of 
MS led to the development of the McDonald cri-
teria in 2001, which introduced MRI results as 
surrogates for the criteria of DIS and DIT.21 This 
resulted in earlier and more sensitive diagnosis.22 
With its revisions in 200523 and 2010,24 the crite-
ria has been further simplified in which a single 
MRI study could fulfill the requirements of DIS 
and DIT. The most recent modifications in 2017 
continue to facilitate the diagnosis by introducing 
changes where the presence of oligoclonal bands 
can fulfill the criteria of DIT.25 In addition, 
requirements for DIS and DIT were further 
broadened to include cortical lesions and sympto-
matic lesions excluding the optic nerve on MRI.
The evolution of MS diagnostic criteria had sig-
nificant implications for clinical trials. As diag-
nostic criteria became more sensitive, more 
patients were diagnosed earlier in the disease 
course. In a population of 309 patients who pre-
sented with clinically isolated syndrome (CIS) 
who were evaluated a year later, 16% of the 
cohort were diagnosed with MS under the Poser 
criteria compared to 44% using the McDonald 
criteria, suggesting patients were diagnosed ear-
lier in their disease course under more recent cri-
teria.26 Another study showed that 50% of 
patients with CIS under the 2001 McDonald cri-
teria would be diagnosed with definite MS within 
a year, while only 20% would under the Poser cri-
teria. The apparently improved prognosis of CIS 
and MS groups is a result of the changing diag-
nostic criteria shifting classification of patients 
from higher risk groups into lower risk groups, an 
effect known as the Will Rogers phenomenon 
and/or lead time bias.27 This limits comparison of 
historical MS populations with modern groups. 
Further, another concern is that when sensitivity 
is increased the risk of false positives (i.e. lowered 
specificity) can often occur. This has only been 
conjectured, and not formally validated.
Defining outcome measurements
In order to determine the efficacy of a potential 
therapeutic agent for MS, investigators were 
challenged with devising meaningful outcome 
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measurements of clinical activity. The complex 
clinical course of MS and the lack of biomarkers 
impeded the development of an objective scale to 
measure and track clinical changes. Prior to 1950, 
evaluations of therapeutic efficacy were conveyed 
by patients’ subjective reports on whether symp-
toms were better, worse, or unchanged, similar in 
concept to modern-day patient-reported out-
comes. The first attempts to develop objective 
scales were made by Arkin and colleagues in 1950 
and Alexander in 1951.28,29 Alexander’s approach 
consisted of complex scales scoring 30 neurologic 
signs, and proved to be cumbersome and lacked 
refinement. In 1955 Kurtzke developed a scale 
that could characterize the disability of a patient 
with MS and reflect changes in clinical status 
while maintaining simplicity.4 The patient was 
assigned a degree of disability from 0 (normal 
neurologic exam) to 10 (death due to MS). The 
DSS was first used in a study of isoniazid as ther-
apy for MS, which was also the first multicenter, 
randomized, placebo-controlled, double-blind 
trial of a disease-modifying therapy (DMT) in 
patients with MS.4,30 The DSS was revised in 
1983 to encompass more resolution with half 
steps rather than unitary increments and has 
become a universally accepted standard for meas-
uring disability in MS.31
The result was the expanded disability status 
scale (EDSS), which has since become the most 
widely used outcome measure in MS trials.32 The 
EDSS has been used to characterize trial popula-
tions and measure objective neurologic changes 
in disease course. It carries the advantage of uni-
fying clinical measurements in large multicenter 
trials and allowing for cross-study comparisons. 
MS clinicians are universally familiar with the 
scale and its widespread acceptance by regulators 
has favored its continued use in trials.33,34 Despite 
the popularity of the EDSS, it is not without flaws 
as the scale has been heavily criticized for high 
inter-rater variability, especially in the earlier 
steps, its disproportionate emphasis on walking, 
exclusion of cognitive impairment, and the scale’s 
inherent nonlinearity.
As DMTs became available in the decades fol-
lowing conception of the EDSS, trials required 
increased sample sizes to detect differences in 
treatment efficacy. In 1994, a task force was 
formed to develop improved outcome measure-
ments and address the shortcomings of the 
EDSS,35 which resulted in the publication of the 
MS functional composite (MSFC) in 1999.36 In 
contrast to the neurologic examination focus of 
the EDSS, the MSFC was created to measure the 
major dimensions in which MS presents. It was 
designed as a clinical trial outcome measure and 
originally designed to capture four domains (i.e. 
ambulation, arm function, cognitive function, 
and vision); vision was excluded due to lack of 
data on which to base inclusion. The MSFC was 
required to correlate with the EDSS and assesses 
function in three domains including gait, upper 
extremity coordination, and cognition. The per-
formance in each component is summarized 
using a Z-score that represents the number of 
standard deviations from a reference population. 
The Z-scores are then averaged into a single com-
posite score providing an outcome measure on a 
continuous scale. The MSFC can be assessed 
quickly and reliably and yields more sensitive 
results than the EDSS and possesses predictive 
validity. It has also been shown to correlate better 
with MRI lesion burden and brain atrophy.37,38 
Despite these advantages, the MSFC scale could 
not replace the EDSS as the established gold 
standard of measuring disability from MS. There 
are problems with the MSFC, some of which can 
be remedied, but the intuitive meaning of a com-
posite Z-score is not easily translated into a clini-
cally meaningful quantity. This caused the FDA 
to have concerns around the original use of the 
MSFC in the IMPACT trial,39 which had major 
negative impacts on its adoption even though it 
has been used in many trials since then.
The increased efficacy of DMTs have redefined 
the goals of therapy, and disease activity-free sta-
tus has become an attainable treatment goal.40,41 
As more patients remain disease free with cur-
rently available DMTs, the concept of ‘no evi-
dence of disease activity’ (NEDA) was proposed 
and adopted in 2013, drawing from the term 
NED used in oncology that refers to complete 
cancer remission without ruling out recurrence.42 
NEDA traditionally comprises assessment of 
relapse rate, new or enlarged T2 or gadolinium-
enhancing MRI lesions, and confirmed disability 
worsening. Clinicians have recognized the merit 
in the assessment of overall response to therapy 
that is not adequately captured by these individ-
ual outcome measures. The concept of NEDA as 
an outcome measure in MS trials has begun to see 
use, and the definition of NEDA continues to 
evolve as new components such as brain atrophy 
and CSF neurofilament levels are incorporated.43 
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Currently, NEDA has not been validated in pro-
spective studies to reflect long-term disease remis-
sion in patients at the individual level, and its 
wider use is limited by the inability of the com-
posite measure to capture specific mechanisms of 
disease. The future of NEDA will likely adopt 
new imaging and fluid biomarkers into treatment 
monitoring, and additional experience with its 
use will result in a more refined and uniform defi-
nition of the concept.
Collaborations in MS trials
The achievements in MS trials are founded on 
collaboration among investigators, patients, phar-
maceutical companies, and regulators. MS socie-
ties across different countries have provided 
significant support with grants and activities that 
fostered collaboration and advanced progress in 
clinical trials. Multinational organizations such as 
the European Committee for Treatment and 
Research in MS and its US counterpart the 
Americas Committee for Treatment and Research 
in MS have played influential roles in the promo-
tion and support of MS clinical trials. These 
organizations were formed during an interna-
tional meeting at Grand Island, NY, USA in 
1982.44 The meeting also led to the formation of 
the Advisory Committee on Clinical Trials of 
New Agents in Multiple Sclerosis of the National 
MS Society, which assisted in the design of future 
trials in the upcoming decades. The meeting rep-
resented active efforts to foster clinical trials and 
served as an important initial step forward for MS 
research and future collaborations and 
organizations.
Advances in information technologies have fos-
tered the development of clinical trials and patient 
databases. Collaborative efforts to create data-
bases for epidemiologic studies and clinical trials 
have been underway since the early part of the 
20th century. The North American Registry 
Committee on MS in Multiple Sclerosis was cre-
ated in 1996 to collect longitudinal data on 
patients with MS and assist with trial enrollment. 
Clinical trial databases such as the large-scale 
database from the Sylvia Lawry Center for MS 
research provides information on over 20,000 
patients with MS. The Multiple Sclerosis 
Outcome Assessments Consortium placebo data-
base provides information on placebo arms of 
clinical trials.45 MSBase is the first online global 
MS registry created in 2004 and now contains 
information on over 55,000 patients with MS.46 It 
has provided important epidemiologic informa-
tion and observational data on a large worldwide 
population with MS.
Conclusion
Clinical trials in MS advanced from develop-
ments that objectively defined and quantified the 
progression of a seemingly erratic disease and 
keen observation that a pathway focused on 
inflammation would lead to benefits if reduced or 
controlled. The introduction and refinement of 
MRI have led to visually quantifiable lesion loads 
that can be used to track radiologic evidence of 
disease burden and confirm periods of exacerba-
tions. The evolving diagnostic criteria have 
increased diagnostic sensitivity and simplified 
enrollment in trials. Clinical outcome measures 
such as the EDSS and MSFC allow objective 
monitoring of disease progression. Together these 
milestones paved the way for significant growth in 
the landscape of MS trials but also created new 
challenges for future trials. The rapid develop-
ment of DMTs in MS has led to the decreased 
feasibility of placebo trials due to ethical consid-
erations and increased difficulty in detecting ther-
apeutic effects compared with existing therapies. 
Fewer resources from competition among trials 
are demanding more efficient designs involving 
shorter studies and fewer patients, but these 
advances are limited by lack of biomarkers or sur-
rogate outcomes. While much has been gained 
from clinical trials in the ongoing investigation to 
find the cause and cure of MS, the future of MS 
trials holds potentials and challenges for the set-
ting of new milestones that must be addressed.
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